« previous next »
Pages: [1]

Author Topic: Infection risks for patients w/MS treated w/Gilenya, Tysabri, Rituxan, injectable therapies  (Read 44 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9670
  • MS diagnosed 1980
  • Location: Pacific Northwest
Infection risks for patients w/MS treated w/Gilenya, Tysabri, Rituxan, injectable therapies
« on: February 11, 2020, 08:05:28 pm »
From JAMA Neurology (February 2020; first published October 2019), "Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies." The researchers found that the beta interferons and Copaxone (glatiramer acetate) had the lowest infection rate, and rituximab had the highest.


http://bit.ly/2SmaGeN
« Last Edit: February 11, 2020, 08:07:03 pm by agate »
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
169 Views 		Last post April 21, 2016, 05:17:20 pm
by agate
2 Replies
104 Views 		Last post October 17, 2019, 09:09:54 pm
by agate
0 Replies
42 Views 		Last post August 07, 2020, 02:51:51 pm
by agate
0 Replies
27 Views 		Last post March 05, 2021, 09:14:55 pm
by agate
0 Replies
21 Views 		Last post November 20, 2021, 09:43:09 pm
by agate